Request for Quotations (RFQ) for the Procurement of Quality Control Testing Services of Locally Manufactured Anti Malarial Drugs in Nigeria
UNOPS
Request for Quotations (RFQ) for the Procurement of Quality Control Testing Services of Locally Manufactured Anti Malarial Drugs in Nigeria
Request for quotation
Reference:
RFQ/2023/47865
Beneficiary countries:
Nigeria
Registration level:
Basic
Published on:
28-Jul-2023
Deadline on:
15-Aug-2023 14:00 0.00
Description
Dear sir/madam,
The United Nations Office for Project Services (hereinafter referred to as UNOPS) is pleased to invite prospective bidders to submit quotations for the provision of Quality Control Testing Services of Locally Manufactured Anti Malarial Drugs in Nigeria in accordance with the UNOPS General Conditions of Contract and the Schedule of Requirements as set out in this Request for Quotation (RFQ).
If you are interested in submitting a quotation in response to this RFQ, please prepare your quotation in accordance with the requirements and process as set out in this RFQ and submit it to UNOPS by the deadline for quotation submission set out in the Section II: Schedule of Requirements
Best Regards,
UNOPS Nigeria
IMPORTANT NOTE: Interested vendors must respond to this tender using the UNOPS eSourcing system, via the UNGM portal. In order to access the full UNOPS tender details, request clarifications on the tender, and submit a vendor response to a tender using the system, vendors need to be registered as a UNOPS vendor at the UNGM portal and be logged into UNGM. For guidance on how to register on UNGM and submit responses to UNOPS tenders in the UNOPS eSourcing system, please refer to the user guide and other resources available at: https://esourcing.unops.org/#/Help/Guides
The United Nations Office for Project Services (hereinafter referred to as UNOPS) is pleased to invite prospective bidders to submit quotations for the provision of Quality Control Testing Services of Locally Manufactured Anti Malarial Drugs in Nigeria in accordance with the UNOPS General Conditions of Contract and the Schedule of Requirements as set out in this Request for Quotation (RFQ).
If you are interested in submitting a quotation in response to this RFQ, please prepare your quotation in accordance with the requirements and process as set out in this RFQ and submit it to UNOPS by the deadline for quotation submission set out in the Section II: Schedule of Requirements
Best Regards,
UNOPS Nigeria
IMPORTANT NOTE: Interested vendors must respond to this tender using the UNOPS eSourcing system, via the UNGM portal. In order to access the full UNOPS tender details, request clarifications on the tender, and submit a vendor response to a tender using the system, vendors need to be registered as a UNOPS vendor at the UNGM portal and be logged into UNGM. For guidance on how to register on UNGM and submit responses to UNOPS tenders in the UNOPS eSourcing system, please refer to the user guide and other resources available at: https://esourcing.unops.org/#/Help/Guides
This tender has been posted through the UNOPS eSourcing system. / Cet avis a été publié au moyen du système eSourcing de l'UNOPS. / Esta licitación ha sido publicada usando el sistema eSourcing de UNOPS. Vendor Guide / Guide pour Fournisseurs / Guíra para Proveedores: https://esourcing.unops.org/#/Help/Guides
First name:
N/A
Surname:
N/A
This procurement opportunity integrates considerations for at least one sustainability indicator. However, it does not meet the requirements to be considered sustainable.
Gender issues
Social
The tender contains sustainability considerations addressing gender equality and women's empowerment.
Examples:
Gender mainstreaming, targeted employment of women, promotion of women-owned businesses.
| Link | Description | |
|---|---|---|
| https://esourcing.unops.org/#/Help/Guides | UNOPS eSourcing – Vendor guide and other system resources / Guide pour fournisseurs et autres ressources sur le système / Guía para proveedores y otros recursos sobre el sistema |
95121908
-
Research or testing facility
New amendment added #2: The purpose of this amendment is to extend the submission deadline to August 15, 2023
Edited on:
08-Aug-2023 14:42
Edited by:
webservice@unops.org
New clarification added: CLARIFICATIONS RECEIVEDWe do not have access to International Pharmacopoeia 10th edition and USP 43rd edition.Would it be possible to provide them to us?Best regardsRESPONSE TO CLARICATIONSDear Bright,Please below is the response to your clarificationsPlease note that all WHO prequalified laboratories have access to the various pharmacopeiaNote that labs without WHO prequalification shall be disqualifiedThanks
Edited on:
07-Aug-2023 13:37
Edited by:
webservice@unops.org
New clarification added: CLARIFICATIONs RECEIVEDWe would like to clarify a few points concerning e-mail contacts 1- for sending the submission2-for sending analysis reports Thank you in advance for your feedback RESPONSES TO CLARIFICATIONSDear Bright,Please below are the responses to the clarificationsThe proposals from bidders shall be submitted on the UNOPS esourcing platform ( Kindly use the esourcing guide at the document section as a guide to submit your proposal).
Edited on:
07-Aug-2023 13:32
Edited by:
webservice@unops.org
New clarification added: CLARIFICATION RECEIVEDFurthermore there are Microbial Limit Tests is listed as part of requirements. We will need to know TAMC, TYMC, S. aureus, E.coli this kind of parameters in detail. See below5.4 Parameters for QC testingIn general, the following tests/parameters should be performed and reported.1. Appearance2. Identification3. Related Substances4. Water Content5. Active Pharmaceutical Ingredient (API) Assay6. Dissolution tests7. Microbial limit test8. Uniformity of weight /Uniformity of Dosage UnitRESPONSE TO CLARIFICATIONSDear Bright,Pleasw below is the response to your clarificationPlease note that all the key required tests have been indicated in the Terms of Reference.Further details will be discussed with the selected laboratory.
Edited on:
07-Aug-2023 13:24
Edited by:
webservice@unops.org
New clarification added: CLARIFICATIONS RECEIVEDKindly clarify few notes from our technical partner:1. Artemether/Lumefantrine 20/120mgNote: (1) Please seek manufacturer for dissolution medium. (2) Conditions for Assay will be used for dissolution and uniformity of dosage unit.1. Sulphadoxine/Pyrimethamine 500/25 mgNote: (1) 2.1 mm diameter column will be used instead of 2.0 mm diameter column (as listed within pharmacopoeia); change permissible by pharmacopoeia. (2) No related substances test within USP.1. For the method reference to be Ph Int 10th Edition, not the latest Ph Int 11th Edition.1. For Artesunate/Amodiaquine 100/270mg, there is no monograph within Ph Int that is for 2-API tablets (only separate monograph exist). Please provide the manufacturer’s in-house method.Looking forward to hearing from you. Thank you.RESPONSES TO CLARIFICATIONS Dear Bright,Please below are the responses to your clarifications.The dissolution medium will be provided to the selected laboratoryConditions of Assay shall be inline with the guidance in the international pharmacopeia (10 edition) which is used for the production. More details will be discussed with the selected labWhere the any details are missing from the Int. Ph. 10th edition, specific alternatives including the manufacturer’s method, shall be discussed and agreed upon with the selected laboratory
Edited on:
07-Aug-2023 13:14
Edited by:
webservice@unops.org
New clarification added: CLARIFICATION RECEIVEDWe request that you kindly extend the closing date by a week? RESPONSE TO CLARIFICATIONSDear Bright,Please the submission deadline has been extended to 14:00UTC on August 10, 2023Thanks
Edited on:
07-Aug-2023 13:09
Edited by:
webservice@unops.org
New clarification added: CLARIFICATIONS RECEIVEDDear Team,Kindly clarify few notes from our technical partner:1. Artemether/Lumefantrine 20/120mgNote: (1) Please seek manufacturer for dissolution medium. (2) Conditions for Assay will be used for dissolution and uniformity of dosage unit.1. Sulphadoxine/Pyrimethamine 500/25 mgNote: (1) 2.1 mm diameter column will be used instead of 2.0 mm diameter column (as listed within pharmacopoeia); change permissible by pharmacopoeia. (2) No related substances test within USP.1. For the method reference to be Ph Int 10th Edition, not the latest Ph Int 11th Edition.1. For Artesunate/Amodiaquine 100/270mg, there is no monograph within Ph Int that is for 2-API tablets (only separate monograph exist). Please provide the manufacturer’s in-house method.Looking forward to hearing from you. Thank you.RESPONSE TO CLARIFICATIONSDear Bright,Please are the responses to your clarifications The dissolution medium will be provided to the selected laboratoryConditions of Assay shall be inline with the guidance in the international pharmacopeia (10 edition) which is used for the production. More details will be discussed with the selected labWhere the any details are missing from the Int. Ph. 10th edition, specific alternatives including the manufacturer’s method, shall be discussed and agreed upon with the selected laboratory
Edited on:
07-Aug-2023 12:48
Edited by:
webservice@unops.org
New amendment added #1: The purpose of this amendment is to extend the submission deadline to August 10, 2023
Edited on:
03-Aug-2023 13:19
Edited by:
webservice@unops.org